Research peptides · For laboratory and scientific research in vitro · Not medications · Not approved for consumption · Adults only (18+)
Tirzepatide
In plain language
Tirzepatide (Mounjaro, Zepbound) is the first dual /GIP agonist. In SURMOUNT-1 — 22.5% weight loss over 72 weeks, superior to Semaglutide.
For researchers
Tirzepatide is the first dual / GIP receptor agonist developed by Eli Lilly. Simultaneously activates both major incretin pathways — (appetite suppression, insulin secretion) and GIP (lipid metabolism, thermogenesis). Under trade names Mounjaro (diabetes) and Zepbound (obesity) -approved. SURPASS-2 clinical trial shows superiority over Semaglutide in type 2 diabetes (HbA1c reduction up to -2.46%). SURMOUNT-1 documents average weight loss of 22.5% over 72 weeks — the strongest result in era to date. Half-life ~5 days. Storage: -20°C lyophilized; reconstituted — 21-28 days at 2-8°C.
Scientific literature
Other peptides
Information about Tirzepatide is based on published scientific research and is intended for research purposes. Not medical advice.
Products related to this peptide are for in vitro laboratory research only. Not approved for human consumption.